Targeting CFTR restoring aggrephagy to suppress HSC activation and alleviate liver fibrosis
We emphasize that CFTR activates aggrephagy and promotes HSC activation and hepatic fibrosis by targeting G3BP1, participating in the TGF-β/Smad2/3 signaling pathway. Overall, CFTR has been identified as a potential therapeutic target for liver fibrosis.
Authors
- Wei Huang (ORCID: https://orcid.org/0000-0002-0541-8612)
- Yongxia Liu (ORCID: https://orcid.org/0000-0001-6125-8599)
- Zhaoxiu Liu (ORCID: https://orcid.org/0000-0003-0154-5232)
- Xiang Shi (ORCID: https://orcid.org/0000-0003-2672-6128)
- Tao Ma (ORCID: https://orcid.org/0000-0001-8101-3046)
- Jing Chen (ORCID: https://orcid.org/0000-0002-5710-8691)
- Cuihua Lu
- Lu Zhang (ORCID: https://orcid.org/0000-0003-4085-2980)
- Yilin Hu (ORCID: https://orcid.org/0000-0003-3300-9004)
Institutions
- Nantong University (CN)
- Affiliated Hospital of Nantong University (CN)
- Anyang Hospital of Traditional Chinese Medicine (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1016/j.intimp.2024.113754
- Citations
- 2
- Primary Topic
- Endoplasmic Reticulum Stress and Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.65